Recently, Meili Technology completed an A+round financing of tens of millions of yuan led by industrial capital Antu Biotechnology. Meili Technology was founded in 2017 and is the first innovative enterprise in China to organically combine upstream nanopore gene sequencing technology with downstream pathogen detection terminal applications. After the completion of this round of financing, Meili will dig deep into user pain points, take the market as the starting point, increase research and development investment, accelerate the launch of a sequencing platform for pathogen detection application scenarios, and fully prepare for the start of the first year of commercialization. Antu Biotech (stock code: 603658) was founded in 1999, focusing on the research and development, manufacturing, integration, and service of in vitro diagnostic reagents and instruments. Its products cover immunology, microbiology, biochemistry, molecular biology, coagulation, and more; In the field of testing, we can provide comprehensive product solutions and overall services for medical laboratories.